Grace Therapeutics Company Insiders

GRCE Stock   3.60  0.09  2.44%   
Grace Therapeutics employs about 6 people. The company is managed by 4 executives with a total tenure of roughly 14 years, averaging almost 3.0 years of service per executive, having 1.5 employees per reported executive. Evaluation of Grace Therapeutics' management performance can provide insight into the firm performance.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Grace Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.

Grace Therapeutics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Grace Therapeutics' future performance. Based on our forecasts, it is anticipated that Grace will maintain a workforce of about 6 employees by February 2026.
 
Yuan Drop
 
Covid

Grace Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.1185) % which means that it has lost $0.1185 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1315) %, meaning that it created substantial loss on money invested by shareholders. Grace Therapeutics' management efficiency ratios could be used to measure how well Grace Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of January 13, 2026, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.22. At present, Grace Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting.
The current year's Common Stock Shares Outstanding is expected to grow to about 14.6 M
The market capitalization of Grace Therapeutics is USD55.99 Million. Grace Therapeutics secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
 
Shares in Circulation  
First Issued
2008-09-30
Previous Quarter
15.9 M
Current Value
15.9 M
Avarage Shares Outstanding
M
Quarterly Volatility
4.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Grace Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Grace Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Grace Therapeutics Workforce Comparison

Grace Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 252. Grace Therapeutics holds roughly 6.0 in number of employees claiming about 2.38% of equities under Health Care industry.

Grace Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Grace Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Grace Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Grace Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Grace Therapeutics Notable Stakeholders

A Grace Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Grace Therapeutics often face trade-offs trying to please all of them. Grace Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Grace Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
String symbol = request.getParameter("s");

About Grace Therapeutics Management Performance

The success or failure of an entity such as Grace Therapeutics often depends on how effective the management is. Grace Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Grace management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Grace management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.48)(0.51)
Return On Capital Employed(0.21)(0.22)
Return On Assets(0.15)(0.16)
Return On Equity(0.14)(0.17)
Please note, the presentation of Grace Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Grace Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Grace Therapeutics' management manipulating its earnings.

Grace Therapeutics Workforce Analysis

Traditionally, organizations such as Grace Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Grace Therapeutics within its industry.

Grace Therapeutics Manpower Efficiency

Return on Grace Therapeutics Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.6M
Net Loss Per Executive2.4M
Working Capital Per Employee3.5M
Working Capital Per Executive5.2M

Complementary Tools for Grace Stock analysis

When running Grace Therapeutics' price analysis, check to measure Grace Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grace Therapeutics is operating at the current time. Most of Grace Therapeutics' value examination focuses on studying past and present price action to predict the probability of Grace Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grace Therapeutics' price. Additionally, you may evaluate how the addition of Grace Therapeutics to your portfolios can decrease your overall portfolio volatility.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals